Component

Tissue-plasminogen-activator-induced fibrin clot lysis in vitro

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. At the same 1 nM and with active PAI-1 present, the same enzyme enhanced tPA-induced clot lysis by 78 +/- 2.0%.

    Nattokinase / subtilisin NAT → Tissue-plasminogen-activator-induced fibrin clot lysis in vitro source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    In vitro fibrin clot system
    exposure
    Subtilisin NAT, 1 nM
    limitations
    The stronger enhancement when PAI-1 is present is the evidence for a second, inhibitor-directed arm. It is one assay in one laboratory.
    organism
    In vitro fibrin clot system
    plain_language
    At the same 1 nM and with active PAI-1 present, the same enzyme enhanced tPA-induced clot lysis by 78 +/- 2.0%.
    primary_references
    The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. (2001) https://pubmed.ncbi.nlm.nih.gov/11325965/ DOI: 10.1074/jbc.M101751200
    route
    In vitro
    tissue
    tPA-induced clot lysis, active recombinant PAI-1 present

    Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 158–158

    Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · In vitro fibrin clot system · source_derived_draft · unverified_draft

    At the same 1 nM and with active PAI-1 present, the same enzyme enhanced tPA-induced clot lysis by 78 +/- 2.0%.
    Complete structured claim and evidence

  2. At 1 nM and without added PAI-1, subtilisin NAT enhanced tPA-induced fibrin clot lysis by 48 +/- 1.4%.

    Nattokinase / subtilisin NAT → Tissue-plasminogen-activator-induced fibrin clot lysis in vitro source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    In vitro fibrin clot system
    exposure
    Subtilisin NAT, 1 nM
    limitations
    Paired with the PAI-1-present arm below. The difference between the two is consistent with an added PAI-1 arm but is not a formal component-additivity model.
    organism
    In vitro fibrin clot system
    plain_language
    At 1 nM and without added PAI-1, subtilisin NAT enhanced tPA-induced fibrin clot lysis by 48 +/- 1.4%.
    primary_references
    The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. (2001) https://pubmed.ncbi.nlm.nih.gov/11325965/ DOI: 10.1074/jbc.M101751200
    route
    In vitro
    tissue
    tPA-induced clot lysis, PAI-1 absent

    Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 147–147

    Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · In vitro fibrin clot system · source_derived_draft · unverified_draft

    At 1 nM and without added PAI-1, subtilisin NAT enhanced tPA-induced fibrin clot lysis by 48 +/- 1.4%.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards